Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Return on Equity (2018 - 2020)

Monopar Therapeutics (MNPR) has disclosed Return on Equity for 3 consecutive years, with 0.37% as the latest value for Q3 2020.

  • Quarterly Return on Equity rose 46.0% to 0.37% in Q3 2020 from the year-ago period, while the trailing twelve-month figure was 0.37% through Sep 2020, up 46.0% year-over-year, with the annual reading at 0.44% for FY2019, 4.0% down from the prior year.
  • Return on Equity hit 0.37% in Q3 2020 for Monopar Therapeutics, up from 0.37% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.32% in Q1 2020 to a low of 2.03% in Q2 2018.
  • Historically, Return on Equity has averaged 0.76% across 3 years, with a median of 0.5% in 2019.
  • Biggest YoY gain for Return on Equity was 130bps in 2019; the steepest drop was -45bps in 2019.
  • Year by year, Return on Equity stood at 0.44% in 2018, then dropped by -15bps to 0.5% in 2019, then grew by 26bps to 0.37% in 2020.
  • Business Quant data shows Return on Equity for MNPR at 0.37% in Q3 2020, 0.37% in Q2 2020, and 0.32% in Q1 2020.